Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inetetamab, a novel anti-HER2 monoclonal antibody, exhibits potent synergistic anticancer effects with cisplatin by inducing pyroptosis in lung adenocarcinoma
Jinfang Cui, Yuchao He, Fuyi Zhu, et al.
International Journal of Biological Sciences (2023) Vol. 19, Iss. 13, pp. 4061-4081
Open Access | Times Cited: 12

Showing 12 citing articles:

Preclinical study of inetetamab combined with atezolizumab to synergistically inhibit HER2 and PD-L1 in the treatment of ovarian cancer
Feiquan Ying, Xuyang Zhou, Mengqing Chen, et al.
Deleted Journal (2025) Vol. 33, Iss. 1, pp. 200938-200938
Open Access
CRKL silencing inhibits melanoma growth and enhances its chemotherapy sensitivity through the PI3K/AKT and NLRP3/GSDMD pathways
Jiashe Chen, Mingyuan Xu, Fei Wu, et al.
Biochemical Pharmacology (2025), pp. 116840-116840
Closed Access
Engineering materials for pyroptosis induction in cancer treatment
Jiayi Liu, Taili Chen, XianLing Liu, et al.
Bioactive Materials (2023) Vol. 33, pp. 30-45
Open Access | Times Cited: 12
Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes
Xinlin Liu, Yunlong Song, Panpan Cheng, et al.
Cancer Treatment Reviews (2024) Vol. 130, pp. 102826-102826
Closed Access | Times Cited: 3
Promotion of stem cell-like phenotype of lung adenocarcinoma by FAM83A via stabilization of ErbB2
Ye Yuan, Hao Liang, Jing-Shan Huang, et al.
Cell Death and Disease (2024) Vol. 15, Iss. 6
Open Access | Times Cited: 2
Cisplatin-induced pyroptosis: a double-edged sword in cancer treatment
Wenyang Lei, Wenting Yu, Yu Zhong, et al.
ONCOLOGIE (2024) Vol. 26, Iss. 5, pp. 711-720
Closed Access | Times Cited: 1
Phase 1b trial of anti‐HER2 antibody inetetamab and pan‐HER inhibitor pyrotinib in HER2‐positive advanced lung cancer
Yihua Huang, Yuanyuan Zhao, Yan Huang, et al.
MedComm (2024) Vol. 5, Iss. 5
Open Access
Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis
Mingxia Jiang, Yue Chai, Jiaxuan Liu, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access
Inetetamab-based therapy in real-world treatment patterns with HER2-positive advanced breast cancer patients: a retrospective single-center study
Mingxia Jiang, Jiaxuan Liu, Maiyue He, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access
Multidisciplinary examples of applications: Papers using the MAL-PD/BD/CI/BI theory/method
Ting-Chao Chou
Elsevier eBooks (2024), pp. 181-218
Closed Access
Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer
Ying Kong, Qi Dong, Peng Jin, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 40, pp. 4367-4375
Closed Access
Interpretable Machine Learning Algorithms Identify Inetetamab‐Mediated Metabolic Signatures and Biomarkers in Treating Breast Cancer
Ning Xie, Dehua Liao, Binliang Liu, et al.
Journal of Clinical Laboratory Analysis (2024)
Open Access
Role of PD‐1 in modulating IFN‐γ‐CXCL9/10‐CXCR3 signaling in breast cancer
Lei Hong, Fang Huang, Zexian Hu, et al.
Journal of Biochemical and Molecular Toxicology (2024) Vol. 38, Iss. 12
Closed Access
Page 1

Scroll to top